Copenhagen, Denmark

Nils L Johansen

This inventor holds 1 USPTO granted patent. Top assignee: Novo Industri A/s. Active years: 1986.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 1986

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nils L Johansen: Innovator in Medicinal Peptides

Introduction

Nils L Johansen is a notable inventor based in Copenhagen, Denmark. He has made significant contributions to the field of medicinal peptides, particularly in the development of novel compounds that have therapeutic applications.

Latest Patents

Johansen holds a patent for the "Use of peptides as medicaments and certain novel peptides." This patent includes certain peptides containing the glucagon.sub.1-21 peptide chain, specifically His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp. These peptides are usable as a medicament or diagnostic tool. The peptide exhibits a spasmolytic effect and an inhibitory effect on gastric acid secretion, similar to glucagon, with negligible metabolic effects. Some of the glucagon fragments described in his patent are considered novel compounds.

Career Highlights

Nils L Johansen is associated with Novo Industri A/S, a leading company in the pharmaceutical industry. His work focuses on the innovative use of peptides in medical applications, contributing to advancements in therapeutic treatments.

Collaborations

Johansen has collaborated with notable colleagues, including Behrend Friedrich Lundt and Karin D Jorgensen. Their combined expertise has furthered research and development in the field of medicinal peptides.

Conclusion

Nils L Johansen's contributions to the field of medicinal peptides highlight his innovative spirit and dedication to improving healthcare through scientific advancements. His patent reflects a significant step forward in the use of peptides as effective medicaments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…